Recently, Boyi Bio Group, a professional manufacturer of biological microspheres, announced that it had completed its Series A financing at the beginning of this year. The total scale of this round of financing exceeded RMB 100 million, led by Jinyu Maowu, followed by Bangsheng Capital, Wei Chi Equity and Mr. Hua Guoping, the founder of Hualan Shares, and Puwan Capital served as the exclusive financial advisor.

Boyi Bio Group owns three major brands, namely Tiandirenhe, Boyi Bio, and ACE, which respectively lay out core raw materials such as purification fillers, IVD microspheres, scientific research reagents and instruments, and other businesses. After 10 years of accumulation, the company has achieved 100% localization of the production supply chain of biological microspheres, and the core raw materials have basically achieved full independent production.

Among the three major brands, Tiandirenhe was established in 2013. It is a high-tech enterprise focusing on the research and development and production of high-quality biological purification fillers and supporting consumables and instruments. It is one of the earliest companies in China to engage in the research and development and production of agarose microspheres. The current maximum production capacity is 3,000L/batch. In recent years, my country's biopharmaceuticals have flourished, and the market size has grown rapidly. The five-year compound growth rate has exceeded 20%, far exceeding the overall pharmaceutical market. Chromatography is the most important method for separation and purification of biopharmaceuticals, and the soft gel of agarose matrix is the chromatography medium with the longest application history and the widest application history. Tiandirenhe has about 300 industrial-grade purification filler products in four categories, including affinity, ion exchange, hydrophobic, and molecular sieve, which widely meet the different needs of life science practitioners. The product has excellent performance, and its core indicators such as particle size, pressure resistance, and loading capacity have reached the level of imported products. It is widely recognized by customers and has served 3,000 global customers.

Based on the in vitro diagnostic industry, the Bo Yi Bio brand provides customers with key raw materials and overall solutions. It has established an advanced technology platform and innovative R&D system around the core raw materials of the in vitro diagnostic industry such as diagnostic microspheres. Adhering to the vision of "making the production process of in vitro diagnostic test reagents more standardized and simpler", it is committed to the localization of core raw materials, breakthroughs and innovations, and creating more value for customers and partners. Its chemiluminescent magnetic beads and other raw materials have been well received by leading companies in the industry.

The ACE brand is oriented to the field of life science research. With the mission of "saving precious time for scientific researchers and promoting the rapid development of the biological industry", it focuses on the development and application of high-efficiency biological reagents and instruments, and is committed to optimizing conventional biological experimental processes, and providing high-efficiency, high-quality, and cost-effective products for the majority of biological researchers. Products such as protein precast gels, rapid membrane transfer instruments and reagents under the ACE brand have been widely recognized by a large number of scientific research customers.

On April 19, the groundbreaking ceremony for the new plant project of Boyi Bio Group was held in the West Taihu Industrial Park. The deputy secretary of the Wujin District Party Committee, the district head, the deputy district head, and the secretary of the Party Working Committee of the West Taihu Science and Technology Industrial Park attended the ceremony. The total investment of the project is 300 million yuan, the land area is about 45 mu, and the planned construction of 45,000 square meters of office, R&D and production buildings is planned. A total of 10 fully automated biological purification filler production lines are designed, with a maximum capacity of 10,000L per batch. The protein fermentation scale is expected to reach 5 tons, and it is expected to be put into use in the second half of 2024. After reaching full production, the production capacity of 50,000L of biological macromolecule purification media will be added, and the annual output value income is expected to reach 450 million yuan.

Fang Li, General Manager of Boyi Bio Group, said: "For the successful completion of this round of financing, I am very grateful to Jinyu Maowu, Bangsheng Capital, Wei Chi Equity and Mr. Hua Guoping of Hualan Shares for their recognition and support for Changzhou Boyi Bio Group. For more than ten years, the company team has insisted on microspheres as the core product, with the goal of "realizing the localization of biological core reagents" and the mission of "providing customers with more choices". Boyi Bio Group has achieved a certain layout in the three fields of industrial purification fillers, in vitro diagnostic raw materials and life science reagents and consumables. Through this round of financing, Boyi Bio Group has better resources and larger operating carriers. We will continue to attract outstanding talents in the industry and continue to focus on the application of microspheres in the biological industry to make products more valuable and customers more satisfied."

Li Hongsen, partner of Jinyumaowu, the lead investor in this round, said: "The upstream supply chain of the pharmaceutical industry has always been the focus of Jinyumaowu in recent years, and biological microspheres are especially the key link that is stuck in the bottleneck. Boyi Bio Group has focused on the research and development and application of biological microspheres for ten years, and has stood out in the wave of domestic substitution in recent years. It has built a 100% independent production closed loop including basic materials, functional microspheres, independent antibody development and process verification, and at the same time has developed three promising application directions of macromolecule pharmaceutical industry market, scientific research market and IVD, and has been widely recognized by customers. We believe that Boyi Bio Group will move towards a more brilliant future under the hard work of the professional, dedicated and entrepreneurially passionate young team led by Mr. Fang".

About Boyi Bio Group

Boyi Bio Group will be committed to the development of upstream and downstream tool products in life sciences, realize product value for customers with professional technology and high-quality services, and take providing customers with more choices as its mission to contribute to the development of life sciences and human life and health.